STUDresearch · Non-peptide

Ostarine

Also known as

MK-2866 · Enobosarm · GTx-024 · S-22 · OTR-AC · VERU-024 · MK2866 · Enobosarm (INN / clinical naming)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Non-peptide Some talk Systemic Oral SARMs (adjacent discourse)

Systemic oral SARM: whole-body androgen-receptor effects, with muscle/bone selectivity claims—not a locally targeted injection.

What people say The community story is a 'milder SARM' for holding muscle in a cut or looking leaner. That reputation sits beside suppression, lipid and liver concerns; clinical low-milligram studies are not proof for higher gym-chart amounts. Doses people talk about

Recomp / cutting discussion~10–15 mg/day oral

Once-daily chart language; cutting discussions sometimes mention ~20 mg. 'First cycle' is community shorthand, not safety validation.

Higher physique discussion~15–25 mg/day oral

Bulking/intermediate-chart range; suppression, lipid and liver concerns are not removed by the 'milder SARM' reputation.

Clinical muscle-wasting arms1 or 3 mg once daily

Separate clinical oral doses, not lower steps in a gym protocol. Elderly/postmenopausal studies also included 0.1 and 0.3 mg.

Reported chart amounts, not recommendations or a progression. Female discussions, higher recreational ranges, oncology arms and PCT amounts stay fully preserved in the notes.

Half-life & effect duration

Half-life in the body: Oral study · meanAbout 22 hours
Same study · individual rangeAbout 13.7–31.3 hours
Felt duration people report: One 8-week accountEarly strength gains, then fatigue and visual concerns
After stopping · community reportsFelt changes fade over days to about 2 weeks

Timing context & sources

How it may feel Logs range from little early change to easier strength retention. One eight-week user reported gains but fatigue and visual complaints amid several changing drugs, then judged the side effects not worth it and credited diet/training as plausible drivers.

Cycles people discuss Charts commonly discuss 6–8 weeks, with 4–6-week and 8–12-week variants. Time-off and SERM/PCT debates are not clinical standards; hormonal recovery can outlast the parent-drug clock. Timing Single daily oral use appears in studies and community discussion, with morning or pre-workout placement mostly a habit preference; split dosing is uncommon. No controlled comparison establishes one clock time as better. Stacks Ostarine appears alone or with Cardarine, MK-677, other SARMs and PCT drugs. Named combinations carry additional risks and make symptoms difficult to attribute; the clinical PK study did not test these physique stacks. Watch for HPTA suppression: Lower total testosterone, libido changes, mood/energy dips, and post-cycle recovery needs — dose- and duration-dependent; clinical total-T drops already seen at 1–3 mg/day in men; recreational 10–30 mg multi-week runs increase community suppression reports.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Mean 22.0 ± 5.8 hours after 3 mg orally in 12 healthy men.

Coss et al., study 1: individual range 13.7–31.3 hours; the glucuronide metabolite is separately measured. Food, formulation, co-medications and studied population matter.

A small clinical PK arm, not gray-market 10–30 mg use, duration of strength effects, hormone recovery or a drug-testing clearance guarantee.

Coss et al. (2016): enobosarm clinical drug-interaction pharmacokinetics (opens in a new tab)Original article PDF, DOI 10.1007/s10637-016-0353-8; Methods pp.459–460, Table 1/Figure 1; study-1 Results p.461; Table 2 p.462 (3 mg alone, n=12, parent t½ 22.0±5.8 h, Tmax 1–2 h). Relevant text, table and footnotes accessed.Small healthy-male clinical arms; a separately measured glucuronide and the tested interacting drugs cannot be treated as parent-drug effects or evidence for recreational combinations.

Felt duration people report

Changes unfold over weeks in logs; gains and adverse symptoms do not define a single duration.

An eight-week account described early strength gains, later fatigue and visual concerns, ending because the experience did not seem worthwhile. The author later credited disciplined diet/training as plausible explanations.

Ostarine amounts and several co-drugs changed during the account. Persistent visual complaints cannot be attributed to one agent; no reliable post-stop recovery clock was established.

Ostarine 8-week cycle experience (opens in a new tab)November 25, 2023 Ok_Literature_9610 OP, full week-by-week 10/20/10/15 mg chronology, SR9011/enclomiphene/tamoxifen/AI changes, final side-effects-over-benefits judgment; same-author reply that disciplined diet/training could explain gains.Self-reported product, symptoms, labs and body composition; multiple changing co-drugs, baseline testosterone context and calorie deficit. Not a solo ostarine safety study or proof of visual-injury causation.

What people say 14

Recomp / cut hold (community): Better composition or less “flatness” while dieting vs diet alone — heavily confounded by protein, training, and product authenticity. forum
Strength continuity: Maintained or slightly improved strength on cuts; not bulk-style steroid jumps. forum
Beginner-SARM reputation: Cast as milder / more approachable entry than RAD-140 or LGD-4033 for first oral runs. forum
Injury-return talk: Easier return-to-training after downtime or layoffs — anecdotal and confounded. anecdote
vs harder SARMs: Milder gains and generally milder subjective sides than LGD/RAD in forum ranking (uncontrolled). forum
Women’s niche: Sometimes preferred over more androgenic options for lean look; virilization risk still debated and under-characterized clinically. forum
Lean mass (elderly Phase 2): Dose-dependent LBM rise across oral 0.1 / 0.3 / 1 / 3 mg/day over ~12 weeks; ~1.3 kg gain over placebo at 3 mg/day (significant); ~0.7 kg at 1 mg non-significant in common write-ups. trial
Fat mass (same design): Small fat-mass decrease often cited (~0.6 kg class figures at higher clinical dose in secondary descriptions). trial
Physical function (trial): Stair-climb / function improvements in some Phase 2 cachexia / elderly designs — not gym 1RM trials. trial
Cancer cachexia Phase 2: Oral 1 mg and 3 mg over ~16 weeks linked to lean-mass gains in cancer populations (Dobs et al.–class data often quoted). trial
NSCLC Phase 3: Enobosarm 3 mg/day improved lean body mass (~0.41–0.47 kg class figures) but failed to meet co-primary muscle-strength / stair-climb power endpoints → development for that indication stopped. trial
GLP-1 adjacency (QUALITY Phase 2b): Oral enobosarm 3 mg or 6 mg + semaglutide in older adults with obesity: primary lean-mass preservation met; pooled ~71% relative reduction in lean-mass loss vs placebo+semaglutide at ~16 weeks; 3 mg often called “best dose” for lean hold (~99% mean relative reduction in lean-mass loss in sponsor topline language); 6 mg did not clearly beat 3 mg on lean preservation. trial
Scale honesty: Clinical LBM deltas (~0.5–1.5 kg class at studied mg) are modest vs supraphysiologic injectable testosterone (often cited ~5–8 kg LBM class at high TE doses over similar windows). trial
Not estrogenic: No aromatization / intrinsic estrogen activity expected — gynecomastia from aromatization not the AAS-style pathway (suppression-related hormone shifts still matter). trial

Doses people talk about 15

Cutting community band: Often ~10–15 mg/day (sometimes up to ~20 mg) while in a deficit. forum
Bulking / intermediate community band: ~15–25 mg/day common intermediate physique range in SARM threads and vendor-style charts. forum
Upper recreational band: ~25–30+ mg/day; some blogs/forums push ≥12-week runs at 10–30 mg — suppression, lipid, and liver talk intensifies; ~10× many core clinical doses. forum
Female discussion band: Often ~5–10 mg/day starting talk with virilization monitoring emphasis; some logs run higher (e.g. ~10–15+ mg) with mixed side reports — not standardized. forum
Capsule product sizes: Gray-market bottles often sold as 5–10 mg capsules or multi-mg liquid research solutions. forum
Once-daily pattern: Single daily oral use appears in studies and community discussion; split dosing is uncommon except by habit preference. The measured half-life does not itself validate a recreational daily dose or require one schedule. forum
Uncertainty: Research-chem purity, identity, and true delivered mg are unverified without third-party testing; “mg on label ≠ mg in body.” forum
Community recomp / mild-cut band: ~10–15 mg oral once daily is repeatedly presented as a “first-cycle” or “beginner start” amount in forum charts. Those labels are community shorthand, not evidence that the amount is safe or suitable for a new user. forum
PK extremes (not physique protocols): Single doses up to ~100 mg in PK work; short ~14-day studies up to ~30 mg/day reported in summaries. trial
Framing: Discussed / community or trial ranges only — not advice, not prescriptions, not safety-validated for physique use. forum
Clinical elderly / LBM arms: Oral 0.1, 0.3, 1, and 3 mg once daily in healthy elderly men and postmenopausal women (~12 weeks). trial
Core clinical lean-mass / cachexia band: Oral 1 mg and 3 mg once daily dominate Phase 2/3 muscle-wasting and elderly designs. trial
Phase 3 cancer-wasting dose: 3 mg/day in two late-stage NSCLC muscle-wasting trials. trial
Breast-cancer research arms: Higher daily doses studied (commonly cited 9 mg and 18 mg Phase 1/2 style; Phase 3 ARTEST-class 9 mg programs discussed). trial
GLP-1 combo trial doses: Enobosarm 3 mg or 6 mg oral daily with semaglutide in QUALITY Phase 2b older-adult obesity design. trial

How it may feel 8

Days 1–7: Little dramatic “buzz”; occasional early pump, fullness, or joint comfort notes; many feel nothing clear. forum
Weeks 1–2: Some report easier strength hold in a deficit or slightly better gym recovery; others still neutral. One eight-week log described strength improvement by week 2 but later fatigue, nipple sensitivity and persistent visual complaints while changing ostarine, SR9011, enclomiphene, tamoxifen and an aromatase inhibitor. The author ultimately felt the sides outweighed benefits and later said diet/training could explain the gains; no individual symptom can be cleanly assigned to ostarine. forumanecdote
Weeks 3–4: Common checkpoint for photos, waist/arm measurements, and strength logs; early libido/energy complaints may start at higher recreational mg. forum
Weeks 4–6: Mid-cycle reassessment window; if no composition or performance signal, community often blames diet, under-eating protein, sleep, or fake product before “more mg.” forum
Weeks 6–8: Most common cycle end for first/solo runs; modest leaner look rather than steroid-scale mass is the expected narrative. forum
Weeks 8–12: Longer runs appear in aggressive logs; suppression, lipid, and “low T” talk intensifies. forum
On-cycle suppression lag: Libido, morning wood, mood, or drive issues often later in cycle or after stopping rather than day 1. forum
Post-cycle 1–2 weeks: Soft drop-off in fullness, pumps, or drive for some as water/glycogen and hormones shift; diet/training still dominate outcomes. anecdote

Cycles people discuss 10

Typical physique length: 6–8 weeks most common on-cycle window in community charts. forum
Shorter blocks: 4–6 weeks for first trials, early stop on sides, or low-confidence product. forum
Longer talk: 8–12 weeks appears in intermediate/advanced and some vendor-style guides; multi-month continuous gray-market use is poorly tracked. forum
Time-off rule of thumb: Off-cycle ≥ on-cycle length is a frequent forum heuristic; not a clinical standard. forum
PCT debate — low/mild runs: Some argue short low-mg solo ostarine needs only natural recovery + bloodwork; others still run a light SERM. forum
PCT debate — higher/longer runs: SERM post-cycle (tamoxifen “Nolvadex” or clomiphene “Clomid” in forum language) commonly discussed after ~8 weeks at mid/high recreational mg — not standardized medical care. forum
Example PCT language (forum charts only): Tamoxifen ~20 mg/day or clomiphene ~25–50 mg/day for ~4 weeks after higher-dose runs is a recurring chart pattern — evidence quality is anecdotal / AAS-derived, not ostarine RCTs. forum
Bloodwork talk: Pre, mid (~week 4–6), and post panels (total/free T, LH/FSH, estradiol, CBC, CMP/liver enzymes, fasting lipids) frequently recommended in harm-reduction threads. forum
Re-runs: Restart after multi-week break and/or normalized labs is common seasonal bulk/cut talk; long-term multi-year safety data for recreational dosing are limited. forum
Bridge / cruise misuse: Continuous low-dose “cruise” appears in some logs; no clinical support for chronic unsupervised SARM exposure. forum

Timing 12

Once-daily context: Both trial and community practice include single daily oral dosing without mandatory splits. That practice is not proved safe or optimal by the terminal half-life alone. forum
Steady-state: Multi-day accumulation expected — not a single-dose “feel” compound. forum
Timing of day: Morning common for habit; some prefer pre-workout — no controlled outcome comparisons. forum
After stop: Subjective effects often fade over days to ~2 weeks; full hormonal/lipid recovery is individual and dose/duration-dependent. forum
Half-life: Human-volunteer summaries commonly cite ~14–24 hours. In Coss et al.'s 3 mg oral study-1 arm, parent enobosarm plasma terminal half-life averaged 22.0 ± 5.8 hours (individual range 13.7–31.3) in 12 healthy men. This is a specific study/formulation estimate, not the duration of gains or hormonal recovery. trial
Absorption: In the 3 mg oral study-1 arm, parent enobosarm plasma Tmax had a median of 1.0 hour (range 1–2 hours). Rapid absorption is not a measured onset of strength, physique or subjective effects. trial
PK linearity: Summaries describe linear/dose-proportional PK over broad single-dose ranges (including high PK doses). trial
Metabolism: Minimal CYP oxidative metabolism (CYP3A4 greatest among CYPs); primary circulating metabolite enobosarm glucuronide via UGT1A1 / UGT2B7. trial
Drug-interaction notes (clinical PK): Strong CYP3A4 inducer rifampin reduced exposure (~AUC −43% class figures); pan-UGT inhibitor probenecid increased exposure (~AUC +50%, t½ +78% class figures); itraconazole minimal impact — low clinically relevant DDI risk concluded in write-ups, still relevant for polypharmacy research. That authors' conclusion concerns the tested interaction program, not absence of interaction risk: the reported exposure changes remain material and do not validate arbitrary multi-drug physique stacks. trial
Hormone timing (clinical low mg): In healthy elderly men, total T fell significantly at 1 mg (−31%) and 3 mg (−57%) class figures; free T / LH / FSH not always significantly changed up to 3 mg in short designs; SHBG dropped sharply (e.g. ~61% men / ~80% women at 3 mg). trial
Lipid timing: Dose-dependent HDL drops cited (~17% at 1 mg/day; ~27% at 3 mg/day in trial summaries); total cholesterol and triglycerides also often down; LDL often relatively unchanged. trial
Detection / sport: WADA-prohibited anabolic agent class; metabolite detection windows matter for tested athletes far beyond “half-life days.” trial

Stacks 12

Solo first-run: Ostarine alone is the default “learn the compound” recommendation in many beginner threads. forum
+ Cardarine (GW-501516): Classic “cut stack” — ostarine for muscle hold + cardarine for endurance/work capacity talk; dual gray-market / toxicity risk (cardarine animal cancer signal often cited). Example chart language: ostarine ~10–20 mg + cardarine ~10–20 mg daily. forum
+ MK-677 (ibutamoren): Recovery, hunger, and sleep narrative on a mild SARM base; multi-axis confound (GH/IGF axis + AR). Chart language often MK-677 ~10–25 mg with ostarine ~10–20 mg. forum
+ Andarine (S4): Recomp / hardening stack talk; S4 vision sides (yellow tint / night vision) are the main extra risk narrative. forum
+ LGD-4033: “Bulk bridge” stack — ostarine mild base + LGD for more mass; suppression and lipid talk rise vs solo osta. Example charts: ostarine ~10–20 mg + LGD ~5–10 mg. forum
+ RAD-140: Strength/size stack; generally ranked more suppressing and harder-hitting than osta alone. forum
Triple cut charts: Andarine + ostarine + cardarine appears in older bodybuilding stack lists (e.g. high-mg S4 + osta ~25 mg + GW ~20 mg class examples in secondary sources) — stacked risk, not a trial protocol. forum
+ PCT (Nolvadex/Clomid talk): Post-cycle SERM recovery stacks heavily debated after mid/high recreational cycles. forum
+ hCG (less common on pure SARM runs): Sometimes borrowed from AAS PCT playbooks when suppression feels deep — not ostarine-specific evidence. forum
Diet/training stack: High-protein deficit or recomp surplus + progressive overload is what most honest logs credit for visible change. forum
Avoid poly-SARM megastacks (harm-reduction view): Multi-SARM capsules (osta + LGD + RAD + MK-677 + GW in one product) show up in liver-injury case series — attribution becomes impossible. trial
GLP-1 clinical adjacency (not a bro stack chart): Enobosarm studied with semaglutide for lean-mass preservation during weight loss — medical trial context, not a fitness product combo. trial

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 8

Watch for 20

Women’s androgenic / virilization risk: Voice deepening, menstrual changes, acne, hair growth — potential masculinizing effects largely under-evaluated clinically; anecdotal forum reports exist; “milder SARM” does not mean zero virilization risk. forum
Estrogen deficiency cascade: Non-aromatizing AR agonists may leave low-E symptoms (joints, mood, libido, bone long-term) if endogenous T/E production is suppressed — mechanism talk, not fully mapped for recreational osta. forum
Source quality: Contamination, under/over-dosing, wrong active, or banned-substance adulteration is common in internet “SARMs.” forum
Alcohol: Concurrent heavy alcohol may compound liver risk narratives in case contexts. forum
Unapproved-drug status: SARMs are not FDA-approved for human use and are not legal dietary-supplement ingredients. This card maps forum talk only — not a sourcing guide, not a safety claim, and not a promise of results. trial
HPTA suppression: Lower total testosterone, libido changes, mood/energy dips, and post-cycle recovery needs — dose- and duration-dependent; clinical total-T drops already seen at 1–3 mg/day in men; recreational 10–30 mg multi-week runs increase community suppression reports. trial
SHBG collapse: Large SHBG reductions at clinical 1–3 mg/day (dramatic % drops in trial summaries) — free-hormone interpretation becomes non-trivial. trial
Lipids: Decreased HDL and adverse lipid-panel shifts repeatedly documented (e.g. ~17% HDL drop at 1 mg; ~27% at 3 mg). trial
Liver enzymes: Transient ALT/AST rises in trials (rates of elevation variously reported from <1% up to ~33% depending on study/definition); occasional marked elevations requiring discontinuation. trial
Hepatotoxicity cases: Published case reports of drug-induced liver injury / cholestatic patterns with enobosarm and multi-SARM products; SARM DILI reports rose notably ~2020–2022. trial
Trial AE list: Headache, fatigue, nausea, diarrhea, anemia, back pain among commonly listed clinical adverse events. trial
Hematology: Small increases in hemoglobin/hematocrit observed at 3 mg/day class data. trial
Metabolic notes: Small decreases in fasting glucose / insulin / insulin-resistance markers reported at 3 mg in some designs — not a diabetes drug. trial
Infertility / HPG axis: Suppression of gonadotropins and sex steroids at higher exposure can impair fertility while on/after cycle; recovery variable. trial
Cardiac / FDA language: FDA has warned that SARMs in bodybuilding products may risk heart attack, stroke, and liver damage among other harms. trial
Stacked product danger: Multi-compound SARM capsules complicate causality when liver or lipid injury appears. trial
Drug testing: Prohibited under WADA anabolic agents; positive tests and career consequences are real for tested athletes. trial
Legal / regulatory: Investigational; not approved as a dietary supplement or medicine for physique use in the US; possession/sale rules vary by jurisdiction. trial
Not risk-free framing: “Milder than steroids” is a relative forum ranking, not a safety claim or medical endorsement. forum
Unknown high-dose risk: Effects and long-term safety of sustained 10–30+ mg/day gray-market use remain poorly characterized vs 1–3 mg clinical programs. trial

Updated: 2026-08-12

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

What people say 14

Doses people talk about 15

How it may feel 8

Cycles people discuss 10

Timing 12

More on what it is 7

Stacks 12

Storage notes 2

Related 8

Watch for 20

Timing context & sources